Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
Hou X, Gong R, Zhan J, Zhou T, Ma Y, Zhao Y, Zhang Y, Chen G, Zhang Z, Ma S, Chen X, Gao F, Hong S, Luo F, Fang W, Yang Y, Huang Y, Chen L, Yang H, Zhang L. Hou X, et al. BMC Cancer. 2018 Jun 7;18(1):641. doi: 10.1186/s12885-018-4559-3. BMC Cancer. 2018. Retraction in: BMC Cancer. 2023 Apr 30;23(1):386. doi: 10.1186/s12885-023-10880-9 PMID: 29879950 Free PMC article. Retracted.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Fang W, et al. Among authors: hou x. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10. Lancet Oncol. 2018. PMID: 30213452 Clinical Trial.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L. Zhou Y, et al. Among authors: hou x. J Immunother Cancer. 2018 Dec 22;6(1):155. doi: 10.1186/s40425-018-0477-9. J Immunother Cancer. 2018. PMID: 30577837 Free PMC article.
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X, Zhao S, Zheng Q, Pan H, Zhang L, Long H, Yang H, Wang X, Wen Z, Wang J, Yang H, Xia X, Zhao Y, Hou X, Ma Y, Zhou T, Zhang Z, Zhan J, Huang Y, Zhao H, Zhou N, Yi X, Zhang L. Zhang Y, et al. Among authors: hou x. Mol Cancer. 2019 Jan 9;18(1):7. doi: 10.1186/s12943-019-0939-9. Mol Cancer. 2019. PMID: 30626401 Free PMC article.
9,930 results